 Theravance Biopharma Inc NASDAQ: TBPH will reduce its headcount by approximately 75 estimated 270 positions, with most of the lay off to complete in November and the remainder in February 2022. The Company sees a total annualized operating expense savings of approximately 165 million in 2022 and expects a positive cash flow beginning in 2H of 2022. 